What is GHRS's health score?

GH Research PLC (GHRS) has a TradeApes health score of 40 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is GHRS's estimated fair value?

Based on our 5-year discounted cash flow model, GH Research PLC's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is GHRS undervalued or overvalued?

Our model currently rates GHRS as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

4 free score cards remaining

GH Research PLC (GHRS)

Healthcare Inconclusive inconclusive weak

$26.77

Updated: 2026-07-14

TradeApes Score

Financial Strength

40 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk Management

65 Healthy

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.